Ligand Bolsters Business Development Team with Healthcare Investment Veterans
Event summary
- Ligand Pharmaceuticals appointed Peter Renehan, MD, and Lee Brown as Vice Presidents of Investments and Business Development, effective March 26, 2026.
- Lauren Hay transitioned to Vice President of Portfolio Strategy and Investments, expanding her role to optimize Ligand’s existing portfolio assets.
- Both new hires will focus on sourcing and transacting royalty financing opportunities, reporting to Paul Hadden, SVP of Investments and Business Development.
The big picture
Ligand’s move to strengthen its business development team aligns with the broader trend of biopharmaceutical companies leveraging external capital to finance late-stage clinical programs. The hires signal a push to capitalize on undervalued opportunities in the royalty financing market, a segment that has seen increased activity as traditional funding sources become more selective. With over 100 assets in its portfolio, Ligand is positioning itself to maintain consistent revenue streams while expanding its market footprint.
What we're watching
- Deal Flow Acceleration
- How the addition of seasoned investors will impact Ligand’s ability to source and close royalty financing deals.
- Portfolio Performance
- Whether Lauren Hay’s expanded role can drive meaningful growth and optimization within Ligand’s existing portfolio.
- Market Differentiation
- The pace at which Ligand can distinguish itself in the competitive royalty financing space with these strategic hires.